Repligen (RGEN) | Financial Analysis & Statements
Repligen Corporation Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
197.9M
Gross Profit
103.8M
52.46%
Operating Income
16.3M
8.26%
Net Income
13.3M
6.71%
EPS (Diluted)
$0.23
Balance Sheet Metrics
Total Assets
2.9B
Total Liabilities
843.6M
Shareholders Equity
2.1B
Debt to Equity
0.40
Cash Flow Metrics
Operating Cash Flow
13.3M
Free Cash Flow
17.4M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Repligen Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 738.3M | 634.4M | 632.4M | 801.5M | 670.5M |
| Cost of Goods Sold | 352.0M | 359.8M | 353.9M | 345.8M | 279.3M |
| Gross Profit | 386.2M | 274.6M | 278.4M | 455.7M | 391.3M |
| Gross Margin % | 52.3% | 43.3% | 44.0% | 56.9% | 58.3% |
| Operating Expenses | |||||
| Research & Development | 54.2M | 43.2M | 42.7M | 43.9M | 34.3M |
| Selling, General & Administrative | 290.5M | 263.4M | 218.6M | 215.8M | 183.9M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 344.7M | 306.6M | 261.3M | 259.8M | 218.1M |
| Operating Income | 41.6M | -31.9M | 17.1M | 195.9M | 173.1M |
| Operating Margin % | 5.6% | -5.0% | 2.7% | 24.4% | 25.8% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 21.5M | 20.7M | 2.5M | 1.2M | 11.3M |
| Other Non-Operating Income | 44.0M | 27.5M | 50.2M | 26.2M | -6.9M |
| Pre-tax Income | 62.4M | -27.0M | 56.7M | 219.1M | 153.5M |
| Income Tax | 13.5M | -1.5M | 21.1M | 33.2M | 25.3M |
| Effective Tax Rate % | 21.6% | 0.0% | 37.2% | 15.1% | 16.4% |
| Net Income | 48.9M | -25.5M | 35.6M | 186.0M | 128.3M |
| Net Margin % | 6.6% | -4.0% | 5.6% | 23.2% | 19.1% |
| Key Metrics | |||||
| EBITDA | 139.7M | 47.6M | 85.7M | 235.6M | 209.0M |
| EPS (Basic) | $0.87 | $-0.46 | $0.64 | $3.35 | $2.33 |
| EPS (Diluted) | $0.86 | $-0.46 | $0.63 | $3.24 | $2.24 |
| Basic Shares Outstanding | 56234000 | 55936751 | 55720000 | 55460000 | 55015000 |
| Diluted Shares Outstanding | 56234000 | 55936751 | 55720000 | 55460000 | 55015000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Repligen Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 566.0M | 757.4M | 751.3M | 523.5M | 603.8M |
| Short-term Investments | 201.6M | - | 0 | 100.3M | 0 |
| Accounts Receivable | 158.6M | 134.1M | 124.2M | 116.2M | 117.4M |
| Inventory | 170.5M | 143.0M | 202.3M | 238.3M | 184.5M |
| Other Current Assets | 27.1M | 20.6M | 19.9M | 17.4M | 19.3M |
| Total Current Assets | 1.1B | 1.1B | 1.1B | 998.1M | 931.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 267.5M | 266.3M | 230.7M | 220.1M | 173.0M |
| Goodwill | 2.6B | 2.5B | 2.4B | 2.1B | 2.1B |
| Intangible Assets | 386.1M | 397.9M | 407.0M | 360.6M | 337.3M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 5.6M | 1.6M | 2.8M | 1.7M | 2.5M |
| Total Non-Current Assets | 1.8B | 1.8B | 1.7B | 1.5B | 1.4B |
| Total Assets | 2.9B | 2.8B | 2.8B | 2.5B | 2.4B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 30.0M | 32.1M | 19.6M | 27.6M | 36.2M |
| Short-term Debt | 21.6M | 15.1M | 75.1M | 291.6M | 263.6M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 5.0M | 17.1M | 13.0M | 14.0M | - |
| Total Current Liabilities | 135.8M | 126.8M | 164.9M | 404.2M | 375.3M |
| Non-Current Liabilities | |||||
| Long-term Debt | 668.4M | 671.1M | 636.7M | 131.4M | 102.5M |
| Deferred Tax Liabilities | 22.5M | 22.8M | 39.3M | 23.0M | 33.5M |
| Other Non-Current Liabilities | 16.9M | 36.2M | 25.4M | 62.3M | 97.1M |
| Total Non-Current Liabilities | 707.7M | 730.2M | 701.4M | 216.7M | 233.0M |
| Total Liabilities | 843.6M | 856.9M | 866.3M | 620.9M | 608.3M |
| Equity | |||||
| Common Stock | 563.0K | 561.0K | 558.0K | 556.0K | 553.0K |
| Retained Earnings | 456.2M | 407.4M | 432.9M | 397.3M | 194.1M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 2.1B | 2.0B | 2.0B | 1.9B | 1.8B |
| Key Metrics | |||||
| Total Debt | 689.9M | 686.2M | 711.8M | 423.0M | 366.1M |
| Working Capital | 1.0B | 939.3M | 946.4M | 593.9M | 556.4M |
Balance Sheet Composition
Repligen Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 48.9M | -25.5M | 35.6M | 186.0M | 128.3M |
| Depreciation & Amortization | 97.0M | 86.6M | 68.6M | 51.0M | 38.4M |
| Stock-Based Compensation | 32.6M | 48.1M | 25.6M | 27.3M | 27.5M |
| Working Capital Changes | -54.9M | 53.3M | 32.3M | -64.2M | -115.1M |
| Operating Cash Flow | 113.4M | 164.1M | 136.1M | 171.7M | 106.0M |
| Investing Activities | |||||
| Capital Expenditures | -23.3M | -25.7M | -36.2M | -84.8M | -67.1M |
| Acquisitions | -70.3M | -54.8M | -186.6M | 0 | -149.9M |
| Investment Purchases | -200.3M | 0 | 0 | -100.0M | 0 |
| Investment Sales | 0 | 0 | 102.3M | 0 | 0 |
| Investing Cash Flow | -296.3M | -79.2M | -120.5M | -184.7M | -217.0M |
| Financing Activities | |||||
| Share Repurchases | 0 | 0 | -14.4M | 0 | 0 |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 0 | 290.1M | 0 | 0 |
| Debt Repayment | 0 | -69.9M | - | -26.0K | -21.0K |
| Financing Cash Flow | -18.4M | -87.2M | 247.9M | -17.1M | -3.0M |
| Free Cash Flow | 91.7M | 142.5M | 74.9M | 38.7M | 47.7M |
| Net Change in Cash | -201.3M | -2.2M | 263.5M | -30.1M | -113.9M |
Cash Flow Trend
Repligen Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
154.30
Forward P/E
52.71
Price to Book
3.55
Price to Sales
10.14
PEG Ratio
-1.10
Profitability Ratios
Profit Margin
6.62%
Operating Margin
8.26%
Return on Equity
2.40%
Return on Assets
0.99%
Financial Health
Current Ratio
8.37
Debt to Equity
32.76
Beta
1.19
Per Share Data
EPS (TTM)
$0.86
Book Value per Share
$37.39
Revenue per Share
$13.13
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| RGEN | 7.5B | 154.30 | 3.55 | 2.40% | 6.62% | 32.76 |
| Intuitive Surgical | 170.1B | 54.97 | 8.99 | 16.69% | 28.38% | 0.95 |
| Becton, Dickinson | 56.1B | 25.40 | 1.75 | 6.96% | 8.01% | 77.28 |
| Baxter International | 9.4B | 86.31 | 1.54 | -13.71% | -8.51% | 160.28 |
| AptarGroup | 8.0B | 21.10 | 2.99 | 15.10% | 10.40% | 57.10 |
| Teleflex | 6.0B | 104.31 | 1.93 | 1.58% | -45.45% | 90.32 |
Financial data is updated regularly. All figures are in the company's reporting currency.






